Turnabout is fair play:use of the bacterial Multivalent Adhesion Molecule 7 as an antimicrobial agent by Krachler, Anne-Marie et al.
 
 
University of Birmingham
Turnabout is fair play
Krachler, Anne-Marie; Ham, Hyeilin; Orth, Kim
DOI:
10.4161/viru.3.1.18172
License:
Creative Commons: Attribution-NonCommercial (CC BY-NC)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Krachler, A-M, Ham, H & Orth, K 2012, 'Turnabout is fair play: use of the bacterial Multivalent Adhesion
Molecule 7 as an antimicrobial agent', Virulence, vol. 3, no. 1, pp. 68-71. https://doi.org/10.4161/viru.3.1.18172
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligible in repository under Creative Commons license.
Checked January 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
© 2012 Landes Bioscience.
Do not distribute.
Turnabout is fair play
Use of the bacterial Multivalent Adhesion Molecule 7 as an antimicrobial agent
Anne Marie Krachler, Hyeilin Ham and Kim Orth*
Department of Molecular Biology; UT Southwestern Medical Center; Dallas, TX USA
Keywords: infection, attachment, adhesin,
phosphatidic acid, fibronectin, Gram-
negative pathogen, anti-adhesion therapy
Submitted: 08/15/11
Revised: 09/21/11
Accepted: 09/21/11
http://dx.doi.org/10.4161/viru.3.1.18172
*Correspondence to: Kim Orth;
Email: Kim.Orth@utsouthwestern.edu
Krachler AM, Ham H, Orth K. Outer membrane
adhesion factor multivalent adhesion molecule 7
initiates host cell binding during infection by
Gram-negative pathogens. Proc Natl Acad Sci
USA 2011; 108:11614–9; PMID:21709226; http://
dx.doi.org/10.1073/pnas.1102360108
Pathogen attachment to host tissues isone of the initial and most crucial
events during the establishment of bacter-
ial infections and thus interference with
this step could be an efficient strategy to
fight bacterial colonization. Our recent
work has identified one of the factors
involved in initial binding of host cells
by a wide range of Gram-negative patho-
gens, Multivalent Adhesion Molecule
(MAM) 7. Interference with MAM7-
mediated attachment, for example by
pre-incubation of host cells with recom-
binant MAM7, significantly delays the
onset of hallmarks of infection, such as
pathogen-mediated cytotoxicity or the
development of other adhesive structures
such as actin pedestals. Thus, we are
trying to develop tools based on MAM7
that can be used to prevent or diminish
certain Gram-negative bacterial infec-
tions. Herein, we describe the use of
bead-coupled MAM7 as an inhibitor of
infection with the clinically relevant
pathogen Pseudomonas aeruginosa.
Bacterial pathogens are faced with a
number of problems when they try to
colonize their host—they have to evade
immune recognition, invade tissues and
modulate cellular signaling events to
promote their own survival. A growing
number of virulence factors are known
to contribute to each of these steps, and
more are being discovered continually.
However, the initial step giving rise to an
infection, the stable attachment of the
pathogen to host cells, is often overlooked
and as a result a lot less well understood
than subsequent events. Many virulence
factors are upregulated dependent on host
cell contact and are often only expressed
at low levels upon the bacteria’s first
encounter with its host.1 Often times,
their expression only commences after the
bacteria receive specific environmental
cues they encounter inside the host, such
as elevated temperature, higher or lower
than usual ion concentrations, or reactive
oxygen species generated as a result of the
induction of the host’s immune response
to infection.2,3 In many cases, the patho-
gens capacity to exert its full virulence is
directly dependent on surface contact
and therefore relies to a high degree on
its ability to establish a stable interaction
with the host cells.4
For example, many pathogens express
and secrete large autotransporter toxins
into the surrounding medium. Delivery of
these toxins often requires their localized
binding to the host membrane, where they
cross into the host cell cytoplasm to exert
their cytotoxic effect.5 Other toxins pen-
etrate the host cell membrane by assem-
bling into a multimeric pore complex, a
feature which is highly dependent on local
toxin concentration and thus only possible
if secreting bacteria and host cells are in
sufficient proximity to each other to avoid
loss of toxin by diffusive processes.6,7
Many Gram-negative pathogens possess
an arsenal of effector proteins which target
host proteins to take over the regulation
of host signaling events and manipulate
them to the pathogens advantage. For
example, effector proteins can inhibit
immune responses, induce autophagy and
trigger reorganization of a cell’s cytoskele-
ton.8,9 The delivery of effector proteins
into host cells is accomplished by type III,
type IV or type VI secretion systems,
needle-like complexes which translocate
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bacterial proteins directly from the bacter-
ial cytoplasm into the host’s cytoplasm.10,11
Establishment of these translocation
machines and correctly timed transfer of
proteins relies on direct contact with the
host cells.12
As such, the initial attachment of patho-
gens to their eukaryotic host is a logical
target of therapeutic interference with
bacterial infections. However, developing
therapeutic tools interfering with bacterial
adhesion remains a major challenge, partly
due to the complexity of synthetic recep-
tor or adhesin analogs and variability in
receptor-adhesin interactions between dif-
ferent pathogens and tissue types.13,14
Although many adhesins are known in
both Gram-positive and Gram-negative
bacteria, their expression is often upregu-
lated as a result of host cell contact and
most of them are highly species-specific.
In addition, many adhesion factors are
large proteins or even multi-subunit
protein complexes requiring dedicated
cellular machinery for their transport to
and assembly at the bacterial outer
membrane.15,16
Our recent work identified an adhe-
sion factor, termed Multivalent Adhesion
Molecule (MAM) 7, which is widely
distributed in Gram-negative bacteria,
and especially animal pathogens. MAM7
consists of an N-terminal hydrophobic
region which is required for outer mem-
brane targeting and anchoring of the
protein. This region is followed by a
stretch of six to seven mammalian cell
entry (mce) domains which are responsible
for host cell binding. Mce domains have
been described previously—a family of
proteins containing one mce domain
followed by a domain of unknown
function has been identified as a factor
promoting cellular attachment and inva-
sion of macrophages by mycobacteria,
although the mechanism underlying the
invasion process was unknown.17,18 In
Gram-negative bacteria, the mce domain
seems to have undergone multiple duplica-
tion events to form a distinct family of
mce-containing proteins which consist of
an N-terminal hydrophobic membrane
targeting region, followed by six or seven
mce domains.
In contrast to other adhesins, MAM7 is
relatively small and constitutively expressed
by bacteria, even prior to host cell
contact. Upon encountering host cells, it
gives the pathogen a distinct advantage,
enabling immediate binding to a broad
range of host cell types independent of
the induction of virulence factors.19 Outer
membrane localization and anchoring of
MAM7 does not require any dedicated
transport machinery—this enabled us to
express the protein at the surface of non-
pathogenic E. coli. The non-pathogenic
E. coli laboratory strain BL21 does not
possess attachment factors for mammalian
host cells, which allowed us to analyze
the contribution of MAM7 to host cell
attachment independent of other factors
promoting pathogen adhesion and dissect
the interactions between MAM7 and the
host cell surface.
We identified two different host cell
receptors for bacterial MAM7—the first
receptor is the extracellular matrix pro-
tein fibronectin, which has previously
been described to serve as a receptor for
a variety of bacterial adhesins. In contrast
to other adhesins, which exclusively bind
fibronectin and have evolved to bind this
ligand with exceptionally high affinity,20-22
MAM7 seems to bind to fibronectin
relatively weakly (KD of 15 mM). This
low affinity interaction is complemented
by a second receptor, phosphatidic acid,
resulting in an overall affinity of MAM7
for host cells that is very high (approx.
apparent KD of 200 nM). The function-
ality of mce domains as phosphatidic acid
binding domain seems to have been
conserved across different families—the
Arabidopsis chloroblast protein Tgl2,
which contains only one mce domain,
also binds PA albeit with lower affinity.23
We hypothesize that the duplication of
mce domains in MAM7 leads to an
acquisition of an entirely new function-
ality, the capability to bind to fibronectin.
By enabling pathogens to establish inter-
actions with two distinct types of host
cell receptors, pathogens have increased
their capacity for initial attachment.
Since attachment to fibronectin seems
to initialize host cell binding by a wide
range of pathogens, we suspected block-
ing the host cell receptors with MAM7
would potentially inhibit infection by
other pathogens. Indeed, we showed that
pre-incubation of mammalian cells with
non-pathogenic E. coli expressing MAM7
could competitively inhibit attachment of
a range of Gram-negative pathogens and
stop them from exerting cytotoxic effects
on host cells (as in the case of Yersinia
pseudotuberculosis, Vibrio cholerae or Vibrio
parahemolyticus) and from establishing
permanent mechanisms of attachment,
such as through formation of actin pedes-
tals (enteropathogenic E. coli, EPEC). Our
current efforts are directed toward deve-
loping improved MAM7-derived tools
that may be used as competitive inhibi-
tors of bacterial attachment and thus as
agents to attenuate a wide range of Gram-
negative bacterial infections.
So far, we have successfully inhibited
infection of cultured mammalian cells by a
number of important enteropathogenic
bacteria. V. cholerae is the causative agent
of cholera, a severe gastrointestinal disease
which is responsible of an estimated 5
million deaths annually and still is one
of the leading causes of infant death.24
V. parahemolyticus is a seafood-borne patho-
gen which usually causes diarrheal disease
but can also lead to wound infections and
septicemia, particularly in immunocom-
promised patients.25 Y. pseudotuberculosis
is also a food-borne pathogen and mainly
causes enteritis or tuberculosis-like symp-
toms in infected animals.26,27 EPEC is
another major agent of infantile diarrhea
and is associated with high mortality
rates.28 For all these pathogens, we obser-
ved a 30 to 70% decrease in pathogeni-
city when host cells were pre-treated with
BL21-MAM7.19
Our recent efforts to further develop a
MAM7-derived agent to attenuate Gram-
negative infections have therefore focused
on two issues: First, we are seeking to
expand the repertoire of pathogens sus-
ceptible to MAM7-based inhibition. As
discussed in our previous work, we have
identified MAM7 homologs in a wide
range of Gram-negative pathogens and
we currently are testing a selection of
them for their susceptibility to MAM7-
based inhibition. One of the pathogens
we focus on is Pseudomonas aeruginosa.
P. aeruginosa thrives in most environ-
ments, including water, soil and on human
skin. In immunocompromised patients, it
can cause catheter-associated lung and
urinary tract infections, but it is also a
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major burden for cystic fibrosis patients
and can cause persistent wound infections,
for example in burn patients.29,30 Due
to its clinical importance, we studied if
P. aeruginosa-mediated cytotoxicity could
be attenuated by MAM7 in a tissue culture
model of infection (Fig. 1). The second
focus of our current studies in MAM7-
based inhibitors is dedicated to finding
alternative modes of delivery. While non-
pathogenic bacteria expressing surface-
bound MAM7 may be a suitable vehicle
for gastrointestinal delivery of MAM7 to
prevent or combat enteric path gens, their
use on an open wound would most likely
exacerbate inflammatory responses and
could therefore have adverse effects on
wound healing. We are therefore studying
alternative modes of delivery for MAM7 to
the site of infection. One such approach
is to immobilize recombinant MAM7 on
the surface of inert polymer beads, which
are similar in size to the bacteria we have
previously used (1 mm). We tested the
efficacy of bead-immobilized MAM7
against P. aeruginosa infection of epithelial
cells and compared it to control beads
displaying GST, which do not bind to
host cells (Fig. 1). In each case, we
counted the number of bound beads per
cell (fluorescent beads were used for ease
of visualization) and determined the cyto-
toxic effect of P. aeruginosa using lactate
dehydrogenase (LDH) release assays.
Upon infection, host cells lyse and release
LDH into the culture medium, which can
be detected colorimetrically and compared
with a standard of detergent-lysed cells
(100% lysis). GST-beads did not show
any significant attachment to host cells
and failed to inhibit infection (Fig. 1A
and C). In contrast, MAM7 beads bound
to host cells (17.1 ± 0.9 beads/cell) and, as
a consequence, attenuated P. aeruginosa-
mediated cell killing (cytotoxicity decrea-
sed from 76% to 4%).
These studies demonstrate that MAM7-
based inhibition may potentially be deve-
loped as a tool to attenuate not only
enteric pathogens but also hospital-
acquired and wound-associated infections,
such as those caused by P. aeruginosa. The
adhesin can be expressed at the surface of
non-pathogenic bacteria but may also be
delivered by alternative routes, such as
immobilized on beads, which may aid in
future applications in decreasing risks
associated with the introduction of live
bacteria into a living organism. In the
future, we hope to be able to extend the
application of MAM7 to include other
clinically relevant Gram-negative patho-
gens and develop tools for its efficient
delivery to the site of potential infection.
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